TNFRSF9 and neoplasm: Despite better or equivalent anti-tumor activity in preclinical models compared with anti-PD-1 and anti-PD-L1 Abs11, two anti-4-1BB Abs entered clinical trials, Urelumab and Utomilumab, remained in early stages.